CONTEXT: Hypercatabolism of high-density lipoprotein (HDL) apolipoprotein (apo) A-I results in low plasma apoA-I concentration. The mechanisms regulating apoA-I catabolism may relate to alterations in very low density lipoprotein (VLDL) metabolism and plasma adiponectin and serum amyloid A protein (SAA) concentrations. OBJECTIVE: We examined the associations between the fractional catabolic rate (FCR) of HDL-apoA-I and VLDL kinetics, plasma adiponectin, and SAA concentrations. STUDY DESIGN: The kinetics of HDL-apoA-I and VLDL-apoB were measured in 50 obese and 37 nonobese men using stable isotopic techniques. RESULTS: In the obese group, HDL-apoA-I FCR was positively correlated with insulin, homeostasis model of assessment for insulin resistance (HOMA-IR) score, triglycerides, VLDL-apoB, and VLDL-apoB production rate (PR). In the nonobese group, HDL-apoA-I FCR was positively correlated with triglycerides, apoC-III, VLDL-apoB, and VLDL-apoB PR and negatively correlated with plasma adiponectin. Plasma SAA was not associated with HDL-apoA-I FCR in either group. In multiple regression analyses, VLDL-apoB PR and HOMA-IR score, and VLDL-apoB PR and adiponectin were independently predictive of HDL-apoA-I FCR in the obese and nonobese groups, respectively. HDL-apoA-I FCR was positively and strongly associated with HDL-apoA-I PR in both groups. CONCLUSIONS: Variation in VLDL-apoB production, and hence plasma triglyceride concentrations, exerts a major effect on the catabolism of HDL-apoA-I. Insulin resistance and adiponectin may also contribute to the variation in HDL-apoA-I catabolism in obese and nonobese subjects, respectively. We also hypothesize that apoA-I PR determines a steady-state, lowered plasma of apoA-I, which may reflect a compensatory response to a primary defect in the catabolism of HDL-apoA-I due to altered VLDL metabolism.
CONTEXT: Hypercatabolism of high-density lipoprotein (HDL) apolipoprotein (apo) A-I results in low plasma apoA-I concentration. The mechanisms regulating apoA-I catabolism may relate to alterations in very low density lipoprotein (VLDL) metabolism and plasma adiponectin and serum amyloid A protein (SAA) concentrations. OBJECTIVE: We examined the associations between the fractional catabolic rate (FCR) of HDL-apoA-I and VLDL kinetics, plasma adiponectin, and SAA concentrations. STUDY DESIGN: The kinetics of HDL-apoA-I and VLDL-apoB were measured in 50 obese and 37 nonobese men using stable isotopic techniques. RESULTS: In the obese group, HDL-apoA-I FCR was positively correlated with insulin, homeostasis model of assessment for insulin resistance (HOMA-IR) score, triglycerides, VLDL-apoB, and VLDL-apoB production rate (PR). In the nonobese group, HDL-apoA-I FCR was positively correlated with triglycerides, apoC-III, VLDL-apoB, and VLDL-apoB PR and negatively correlated with plasma adiponectin. Plasma SAA was not associated with HDL-apoA-I FCR in either group. In multiple regression analyses, VLDL-apoB PR and HOMA-IR score, and VLDL-apoB PR and adiponectin were independently predictive of HDL-apoA-I FCR in the obese and nonobese groups, respectively. HDL-apoA-I FCR was positively and strongly associated with HDL-apoA-I PR in both groups. CONCLUSIONS: Variation in VLDL-apoB production, and hence plasma triglyceride concentrations, exerts a major effect on the catabolism of HDL-apoA-I. Insulin resistance and adiponectin may also contribute to the variation in HDL-apoA-I catabolism in obese and nonobese subjects, respectively. We also hypothesize that apoA-I PR determines a steady-state, lowered plasma of apoA-I, which may reflect a compensatory response to a primary defect in the catabolism of HDL-apoA-I due to altered VLDL metabolism.
Authors: Susan Sam; Steven Haffner; Michael H Davidson; Ralph D'Agostino; Alfonso Perez; Theodore Mazzone Journal: J Clin Endocrinol Metab Date: 2011-11-09 Impact factor: 5.958
Authors: Ronald B Goldberg; Marinella Temprosa; Lisa Mele; Trevor Orchard; Kieren Mather; George Bray; Edward Horton; Abbas Kitabchi; Jonathan Krakoff; Santica Marcovina; Leigh Perreault; Neil White Journal: Metabolism Date: 2015-12-02 Impact factor: 8.694
Authors: Arthur McCullough; Stephen F Previs; Jaividhya Dasarathy; Kwangwon Lee; Abdullah Osme; Chunki Kim; Serguei Ilchenko; Shuhui W Lorkowski; Jonathan D Smith; Srinivasan Dasarathy; Takhar Kasumov Journal: Am J Physiol Endocrinol Metab Date: 2019-09-10 Impact factor: 4.310
Authors: Lars P Sørensen; Esben Søndergaard; Birgitte Nellemann; Jens S Christiansen; Lars C Gormsen; Søren Nielsen Journal: Diabetes Date: 2011-08-01 Impact factor: 9.461
Authors: Elena V Shabrova; Olga Tarnopolsky; Ajay P Singh; Jorge Plutzky; Nicholi Vorsa; Loredana Quadro Journal: PLoS One Date: 2011-10-10 Impact factor: 3.240
Authors: Juan-Patricio Nogueira; Marie Maraninchi; Sophie Béliard; Anne Marie Lorec; Bruno Berthet; Audrey Bégu-Le Corroller; Noémie Dubois; Rachel Grangeot; Catherine Mattei; Jean Gaudart; Alain Nicolay; Henri Portugal; Bernard Vialettes; René Valéro Journal: Nutr Metab (Lond) Date: 2012-03-13 Impact factor: 4.169